Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies
Seminars in Thrombosis and Hemostasis · 01.09.2026 · 52 (06) · 653-666
DOI: 10.1055/a-2768-2477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.09.2026. Verfasst von Fabian Sanchis-Gomar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Lipoprotein(a), Risk Management. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Lipoprotein(a) (Lp(a)) is a genetically determined, lifelong cardiovascular risk factor strongly associated with atherosclerotic cardiovascular disease (ASCVD) despite optimal low-density lipoprotein cholesterol (LDL-C) lowering. The current management is challenged by the absence of outcome-proven Lp(a)-specific therapies. Statins, ezetimibe, bempedoic acid, and lifestyle interventions have little or no effect on Lp(a). Statins may modestly raise levels; niacin is now contraindicated as it has not been shown to reduce cardiovascular or all-cause mortality, while PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibitors and inclisiran reduce Lp(a) concentrations by approximately 20 to 30%, though this effect remains secondary to their LDL-C-lowering effect. The only U.S. Food and Drug Administration (FDA)-approved therapy specifically addressing Lp(a) is lipoprotein apheresis, which reduces Lp(a) levels by 60 to 75%, but is restricted to specific patient populations due to invasiveness, high cost, and limited availability. Future promise lies in RNA-based therapies, including antisense oligonucleotides (pelacarsen) and small-interfering RNAs (olpasiran, lepodisiran, SLN360), which achieve 80 to 95% sustained Lp(a) reductions. Large outcome trials will determine whether this biochemical efficacy translates into tangible clinical benefits. Current guidelines now recommend one-time lifetime Lp(a) measurement, treating ≥125 nmol/L (≥50 mg/dL) as a risk-enhancing factor. High or extreme elevations, especially with ASCVD, mandate aggressive LDL-C lowering, optimization of modifiable risk factors, family cascade screening, and apheresis or referral to RNA-therapy trials in select cases. Thus, while therapeutic options remain limited, systematic measurement and risk stratification are ethically justified to prepare for the imminent arrival of Lp(a)-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.
- Department of Health Sciences, University of Burgos, Burgos, Spain.
- Section of Clinical Biochemistry, School of Medicine, University of Verona, Verona, Italy.
ORCID-Profile: Giuseppe Lippi
Zitieren
APA
Sanchis-Gomar, F., & Lippi, G. (2026). Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies. Seminars in Thrombosis and Hemostasis, 52(06), 653-666. https://doi.org/10.1055/a-2768-2477
Vancouver
Sanchis-Gomar F, Lippi G. Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies. Seminars in Thrombosis and Hemostasis. 2026;52(06):653-666. doi:10.1055/a-2768-2477
BibTeX
@article{SanchisGomar2026,
author = {Sanchis-Gomar, Fabian and Lippi, Giuseppe},
title = {Clinical Response to Elevated Lipoprotein(a): Practical Approach for Risk Management in the Absence of Targeted Therapies},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {06},
pages = {653--666},
doi = {10.1055/a-2768-2477}
}
EUVIMED